
Satsuma Pharmaceuticals STSA
Quarterly report 2023-Q1
added 05-11-2023
Satsuma Pharmaceuticals ROE Ratio 2011-2026 | STSA
Annual ROE Ratio Satsuma Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -149.61 | -50.5 | -66.12 | -24.43 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -24.43 | -149.61 | -72.66 |
Quarterly ROE Ratio Satsuma Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -94.16 | -62.52 | -74.04 | -63.43 | -50.15 | -28.36 | -45.7 | -50.92 | -57.32 | -66.12 | -58.14 | -48.56 | -38.35 | -24.43 | 4.26 | 24.51 | 56.61 | 59.05 | 39.73 | 26.64 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 59.05 | -94.16 | -27.57 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
7.27 | $ 18.06 | - | $ 28.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 19.44 | -0.46 % | $ 909 M | ||
|
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | ||
|
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
-294.78 | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
-91.56 | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | ||
|
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | ||
|
Protara Therapeutics
TARA
|
-29.24 | $ 5.03 | -3.08 % | $ 215 M | ||
|
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | ||
|
Tarsus Pharmaceuticals
TARS
|
-19.34 | $ 67.0 | -0.3 % | $ 2.8 B | ||
|
bluebird bio
BLUE
|
-108.93 | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - | ||
|
Theravance Biopharma
TBPH
|
20.57 | $ 14.9 | -1.91 % | $ 750 M | ||
|
Avid Bioservices
CDMO
|
-231.16 | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.2 | -6.97 % | $ 306 M | ||
|
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B | ||
|
Bio-Techne Corporation
TECH
|
3.83 | $ 51.31 | -2.65 % | $ 8.08 B | ||
|
Tenax Therapeutics
TENX
|
-54.19 | $ 14.64 | -2.2 % | $ 574 M | ||
|
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
-207.61 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
-46.05 | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-63.65 | $ 1.07 | -2.29 % | $ 21.9 M | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
17.83 | $ 28.76 | -3.43 % | $ 32.9 B | ||
|
Enochian Biosciences
ENOB
|
833.76 | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | ||
|
Equillium
EQ
|
-78.32 | $ 2.03 | -1.46 % | $ 116 M | ||
|
Eton Pharmaceuticals
ETON
|
-17.59 | $ 23.81 | 1.51 % | $ 641 M | ||
|
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | ||
|
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 46.38 | -2.45 % | $ 4.17 B |